A flucytosine-resistant Cryptococcus neoformans (serotype D) strain isolated in Turkey from cutaneous lesions

References

• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Gun Micro biol Rev 1995; 8: 515–548.
   Web of Science ®Google Scholar
• Cox GM, Perfect JR. Cryptococcus neoformans var. neoformans and gauii and Trichosporon species. In: Collier L, Balows A, Sussman M, eds. Topley, and Wilson's Microbiology and Microbial Infections. 9th edn, Vol. 4. Ajello L, Hay RJ, vol. eds. Medical Mycology. London: Arnold, 1998: 461–486.
   Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. NEJM 1979; 301: 126–131.
   PubMed Web of Science ®Google Scholar
• Powderly WG. Cryptococcosis. J Int Assoc Physicians AIDS Care 1996; 2: 28–31.
   Google Scholar
• Viudes A, Peman J, Canton E, et al. The activity of combina-tions of systemic antimycotic drugs. Rev Esp Quimioter 2001; 14: 30–39.
   PubMedGoogle Scholar
• Currie BP, Ghannoum M, Bessen L, et al. Decreased flucona-zole susceptibility of a relapse Cryptococcus neoformans isolate after fluconazole treatment. Infect Dis Clin Pract 1995; 4: 318–319.
   Google Scholar
• National Committee for Laboratory Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. Approved Standard; Document M27-A National Committee for Laboratory Standards. Villanova, 1997.
   Google Scholar
• Espinel-Ingroff A, Barchiesi F, Hazen CK, et al. Standardiza-tion of antifungal susceptibility testing and clinical relevance. Med Mycol 1998; 36 (Supp1.1): 68–78.
   Google Scholar
• Rex J, Pfaller M, Galgiani J, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–247.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Clinical utility of in vitro antifungal suscept-ibility testing. Rev Esp Quimioter 2000; 13: 161–166.
   PubMedGoogle Scholar
• Kwon Chung KJ, Bennett JE. Medical Mycology. Philadelphia: Lea and Febiger, 1992: 397–446.
   Google Scholar
• Warren N, Hazem KC. Candida, Cryptococcus and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA, et al., eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 1995: 723–737.
   Google Scholar
• Gatti M, Di Silverio A, Cespa M, et al. Primary unusual cutaneous cryptococcosis in an HIV former drug-abuser patient Mycoses 1996,40: 101–102.
   Google Scholar
• Unat EK, Pars B, Koysak J. Bir kolon cryptococcosis'i vakasi (A case of colonic cryptococcosis). Istanbul Tp Fak Mec 1959; 22: 1318.
   Google Scholar
• Aller Al, Martin-Mozuelos E, Lozano F, et aL Correlation of fluconazole MICs with clinical outcome in cryptococcal infec-tion. Antimicrob Agents Chemother 2000; 44: 1544–1548.
   PubMed Web of Science ®Google Scholar
• Jessup CJ, Pfaller MA, Messer SA, et al. Fluconazole suscept-ibility testing of Cryptococcus neofotmang comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J Clin Microbio/ 1998; 36: 2874–2876.
   PubMedGoogle Scholar
• Rodriguez-Tudela JL, Martin-Diez F, Cuenca-Estrella M, et aL Influence of shaking on antifungal susceptibility testing of Cryptococcus neofotmang a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob Agents Chemother 2000; 44: 400–404.
   PubMedGoogle Scholar
• Richardson MD, Warnock DW. Fungal Infection. Diagnosis and Management. 2nd edn. London: Blackwell Science; 1997:20–58.
   Google Scholar
• Nailer MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999; 43: 169–171.
   PubMedGoogle Scholar
• Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafme against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42: 1057–1061.
   Google Scholar
• Ryder NS. Activity of terbinafme against serious fungal pathogens. Abstracts of 5th Congress of the European Confederation of Medical Mycology (3-6 June 1999, Dresden, Germany). Mycoses 1999; 42: 156–157.
   Google Scholar
• Hiratani T, Asagi I, Yamaguchi H. Evaluation of in vitro antimycotic activity of terbinafme, a new allylamine agent. Jpn J Med Mycol 1991; 32: 323–332.
   Google Scholar
• Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322–328.
   PubMed Web of Science ®Google Scholar
• Van der Horst C, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with immunodeficiency syndrome. NEJM 1997; 337: 15–21.
   PubMed Web of Science ®Google Scholar
• Nguyen MB, Barchiesi F, McGough DA, et al. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995; 39: 1691–1695.
   PubMedGoogle Scholar
• Cook PP. Successful treatment of cryptococcal osteomyelitis and paraspinous abscess with fluconazole and flucytosine. South Med J 2001; 94: 936–938.
   PubMedGoogle Scholar
• Mayanjz-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26: 1362–1366.
   Google Scholar
• Vanden Bossche H, Warnock DW, et aL Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994; 32: 189–202.
   PubMedGoogle Scholar
• Bennett JE. Flucytosine. Ann Intern Med 1977; 86: 319–322.
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Carver PL. Antifungal agents in the 1990s. Drug 1997; 53: 539–549.
   PubMed Web of Science ®Google Scholar
• Viviani MA. Flucytosine-what is its future? J Antimicrob Chemother 1995; 35: 241–244.
   PubMed Web of Science ®Google Scholar
• Whelan WL. The genetic basis of resistance to 5-fluorocytosine in Candida species and Ctyptococcus neoformans. Clin Rev Microbiol 1987; 15: 45–56.
   Google Scholar
• White TC, Man KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Gun Microbiol Rev 1998; 11: 382–402.
   Google Scholar
• Iwata K. Drug resistance in human pathogenic fungi. Eur J Epidemiol 1992; 8: 407–421.
   PubMed Web of Science ®Google Scholar
• Balkis MM, Leidich SD, Mukherjee PK, et al. Mechanisms of fungal resistance: an overview. Drugs 2002; 62: 1025–1040.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Arzeni D, Caselli F, et al. Primary resistance to flucytosine among clinical isolates of Candida spp. J Antimicrob Chemother 2000; 45: 408–409.
   PubMedGoogle Scholar
• Auger P, Dumas C, Joly J. A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine. J Infect Dis 1979; 139: 590–594.
   Google Scholar
• Weber S, Polak A. Susceptibility of yeast isolates from defined German patient groups to 5-fluorocytosine. Mycoses 1992; 35: 163–171.
   PubMedGoogle Scholar
• Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, et al. Flucy-tosine primary resistance in Candida species and Cryptococcus neoformans. Eur J Gun Microbiol Infect Dis 2001; 20: 276–279.
   PubMed Web of Science ®Google Scholar
• Sivrel A, Tiimbay E. Izmir 'de giivercin diskisindan izole edilen Cryptococcus neoformans suslari ve bunlam amfoterisin B'ye in vitro duyarllklar. nfeksiyon Derg 1993; 7: 107–113.
   Google Scholar
• Yidran ST, Saracli MA, Fothergill AW, et al. In vitro suscept-ibility of environmental C. neoformans var. neoformans isolates from Turkey to six antifungal agents, including SCH 56592 and voriconazole. Eur J Gun Microbiol Infect Dis 2000; 19:317–319.
   Google Scholar